Progesterone - Promoter or inhibitor of breast cancer

Climacteric

Volumn 16, Issue S1, 2013, Pages 54-68

  Kuhl, H ^a   Schneider, H P G ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Breast cancer; Endometrial cancer; Mammographic density; Micronized progesterone; Progesterone metabolism; Proteoglycans; Serum progesterone levels

Indexed keywords

AGGRECAN; AGRIN; BIGLYCAN; BREVICAN; COLLAGEN TYPE 17; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GLYPICAN; GROWTH HORMONE; LUMICAN; MEDROXYPROGESTERONE ACETATE; NEUROCAN; PERLECAN; PHOSPHACAN; PROGESTERONE; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROTEIN BCL 2; PROTEOGLYCAN; SERGLYCIN; SYNDECAN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VERSICAN;

ARTICLE; BODY MASS; BREAST CANCER; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER INHIBITION; CANCER RISK; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; EXTRACELLULAR MATRIX; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR PROMOTION;

ADULT; AGED; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MAMMARY GLANDS, HUMAN; MIDDLE AGED; POSTMENOPAUSE; PREGNANCY; PROGESTERONE; RISK FACTORS;

EID: 84880269521     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.768806     Document Type: Article

References (103)

1. Dietel M. H ormone replacement therapy (HRT), breast cancer and tumor pathology. Maturitas 2010; 65 : 183-9
2. Keeling JW, Ozer E, King G, Walker F. O estrogen receptor alpha in female fetal, infant, and child mammary tissue. J Pathol 2000; 191 : 449-51 (Pubitemid 30649915)
3. Schneider HP, Bö cker W. Hormones and progeny of breast tumor cells. Climacteric 2006 ; 9 : 88-107
4. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2011 ; 2 : 85-90
5. Anderson E, Clarke R B. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004; 9 : 3-13 (Pubitemid 39137493)
6. Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab 2004 ; 15 : 316-23 (Pubitemid 39180006)
7. Ferguson J P, Anderson T J. M orphological evaluation of cell turnover in relation to the menstrual cycle in the " resting " human breast. Br J Cancer 1981; 44 : 177-81 (Pubitemid 11039573)
8. Conneely O M, Jericevic B M, Lydon J P. P rogesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2003 ; 8 : 205-14 (Pubitemid 38129942)
9. S haaban AM, O'Neill PA, Davies MP, et al. Declining estrogen receptor-beta expression defi nes malignant progression of human breast neoplasia. Am J Surg Pathol 2003 ; 27 : 1502-12 (Pubitemid 37486611)
10. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000 ; 21 : 40-54 (Pubitemid 32260395)
11. Dwivedy I, Devanesan P, Cremonesi P ; Rogan E, Cavalieri E. Synthesis and characterization of estrogen 2,3-And 3,4-quinones. Comparison of DNA adducts formed by the quinines versus horseradish peroxidase-Activated catechol estrogens. Chem Res Toxicol 1992 ; 5 : 828-33 (Pubitemid 23004873)
12. Mueck AO, Seeger H. Breast cancer: Are oestrogen metabolites carcinogenic? Maturitas 2007 ; 57 : 42-6 (Pubitemid 46602890)
13. Obi N, Vrieling A, Heinz J, Chang-Claude J. Estrogen metabolite ratio: Is the 2-hydroxyestrone to 16 〈-hydroxyestrone ratio predictive for breast cancer? Int J Women's Health 2011 ; 3 : 37-51
14. Eden J A. B reast cancer, stem cells and sex hormones. 3, The impact of the menopause and hormone replacement. Maturitas 2011 ; 68 : 129-36
15. Dontu G, El-Ashry, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004 ; 15 : 193-7 (Pubitemid 38833988)
16. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006 ; 13 : 617-28 (Pubitemid 43886681)
17. Joshi PA, Di Grappa MA, Khokha R. Active allies: Hormones, stem cells and the niche in adult mammopoiesis. Trends Endocrinol Metab 2012 ; 23 : 299-309
18. MacMahon B, Cole P, Lin TM, et al. Age at fi rst birth and breast cancer risk. Bull World Health Organ 1970 ; 43 : 209-21
19. Russo IH, Russo J. Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia 2011 ; 16 : 221-33
20. Russo J, Balogh GA, Heulings R, et al. Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev 2006 ; 15 : 306-42 (Pubitemid 44060488)
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison FJ, Clarke MF. Prospective identifi cation of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003 ; 100 : 3983-8 (Pubitemid 36418143)
22. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Re-Analysis of nine prospective studies. J Natl Cancer Inst 2002 ; 94 : 606-16
23. Thijssen JHH. Local biosynthesis and metabolism of oestrogens in the human breast. Maturitas 2004 ; 49 : 25-33 (Pubitemid 39209368)
24. Vermeulen A, Deslypere J P, Paridaens R, Leclercq G, Roy F, Heuson JC. Aromatase, 17beta-hydroxysteroid dehydrogenase, and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol 1986 ; 22 : 515-25 (Pubitemid 16113813)
25. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol 2003 ; 86 : 245-53 (Pubitemid 37420000)
26. Yaghjyan L, Colditz G A. E strogens in the breast tissue: A systematic review. Cancer Causes Control 2011 ; 22 : 529-40
27. Stefanick M L, Anderson G L, Margolis K L, et a l. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006 ; 295 : 1647-57
28. Welch H G, Black W C. U sing autopsy series to estimate the disease " reservoir " for ductal carcinoma in situ of the breast: How much more breast cancer can we fi nd? Ann Intern Med 1997 ; 127 : 1023-8 (Pubitemid 27516615)
29. Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-Aged women: A study of 110 medicolegal autopsies. Br J Cancer 1987 ; 56 : 814-19 (Pubitemid 18048359)
30. Menard S, Casalini P, Agresti R, Pilotti S, Balsari A. P roliferation of breast carcinoma during menstrual phases. Lancet 1998 ; 352 : 148-9 (Pubitemid 28321343)
31. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: Current understanding and future prospects. Breast Cancer Res 2011 ; 13 : 223-34
32. Boyd N F, Rommens J M, Vogt K, et a l. M ammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005 ; 6 : 798-808 (Pubitemid 41430721)
33. Yaffe M, Hendrix S, Pike M, Santen R, Eden J, Genazzani AR. Is mammographic density, as currently measured, arobust surrogate marker for breast cancer? Gynecol Endocrinol 2005 ; 21(Suppl 1) : 17-21 (Pubitemid 41345496)
34. Gram IT, Funkhouser E, Tabar L. Reproductive and menstrual factors in relation to mammographic parenchymal patterns among perimenopausal women. Br J Cancer 1995 ; 71 : 647-50
35. Greendale G A, Palla S L, Ursin G, et a l. T he association of endogenous sex steroids and sex steroid binding proteins with mammographic density: Results from the Postmenopausal Estrogen/ Progestin Interventions (PEPI) Mammographic Density Study. Am J Epidemiol 2005 ; 162 : 826-34 (Pubitemid 41541366)
36. Johansson H, Gandini S, Bonanni B, et a l. R elationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women. Breast Cancer Res Treat 2008 ; 108 : 57-67 (Pubitemid 351623237)
37. Vachon CM, Sasano H, Ghosh K, et a l. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011 ; 125 : 243-52
38. Checka C M, Chun J E, Schnabel F R, Lee J, Toth H. T he relationship of mammographic density and age: Implications for breast cancer screening. AJR 2012 ; 198 : W292-5
39. Morimoto L M, White E, Chen Z, et a l. O besity, body size, and risk of postmenopausal breast cancer: The Women's Health Initiative (United States). Cancer Causes Control 2002 ; 13 : 741-51 (Pubitemid 35204050)
40. Lahmann P H, Lissner L, Gullberg B, Olsson H, Berglund G. A prospective study of adiposity and postmenopausal breast cancer risk: The Malm ö Diet and Cancer Study. Int J Cancer 2003 ; 103 : 246-52 (Pubitemid 35461518)
41. Feigelson H S, Jonas C R, Teras L R, Thun M J, Calle E E. W eight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomark Prev 2004 ; 13 : 220-4 (Pubitemid 38222552)
42. van den Brandt P A, Spiegelman D, Yaun S S, et a l. P ooled analysis of prospective cohort studies on height, weight and breast cancer risk. Am J Epidemiol 2000 ; 152 : 514-27
43. Speroff L. T he meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002 ; 42 : S31-5
44. Kerlikowske K, Cook A J, Buist D SM, et a l. B reast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010 ; 28 : 3830-7
45. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 1999 ; 130 : 262-9 (Pubitemid 29091853)
46. Greendale G A, Reboussin B A, Slone S, Wasilauskas X, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003 ; 95 : 30-7 (Pubitemid 36124293)
47. Chlebowski R T, Hendrix S L, Langer R D, et a l. I nfl uence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003 ; 289 : 3243-53 (Pubitemid 37430077)
48. Kuhl H. Is the elevated breast cancer risk observed in the WHI study an artifact? Climacteric 2004 ; 7 : 319-23
49. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005 ; 97 : 1366-75
50. Boyd N F, Martin L, Chavez S, et a l. B reast tissue composition and other risk factors for breast cancer in young women: A cross-sectional study. Lancet Oncol 2009 ; 10 : 569-80
51. Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the " resting " human breast: Infl uence of parity, contraceptive pill, age and laterality. Br J Cancer 1982 ; 46 : 376-82 (Pubitemid 12029884)
52. Navarrete MA, Maier CM, Fakzoni R. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle. Breast Cancer Res 2005 ; 7 : R306-13
53. Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg 1996 ; 83 : 1037-46 (Pubitemid 26291203)
54. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003 ; 5 : R129-35
55. Guo YP, Martin L, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomark Prev 2001 ; 10 : 243-8 (Pubitemid 34288536)
56. Li T, Sun L, Miller N, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005 ; 14 : 343-9 (Pubitemid 40270095)
57. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986 ; 10 : 382-93 (Pubitemid 16066440)
58. Graham SJ, Stanchev PL, Lloyd-Smith JOA, Bronskill MJ, Plewes DB. Changes in fi broglandular volume and water content of breast tissue during the menstrual cycle observed by MR Imaging at 1.5 T. JMRI 1995 ; 5 : 695-701
59. Stoeckelhuber M, Stumpf P, Hoefter E A, Welsch U. P roteoglycan-collagen associations in the non-lactating human breast connective tissue during the menstrual cycle. Histochem Cell Biol 2002 ; 118 : 221-30
60. Warren R, Lakhani S R. C an the stroma provide the clue to the cellular basis for mammographic density? Breast Cancer Res 2003 ; 5 : 225-7 (Pubitemid 37080848)
61. Haslam S Z, Woodward T L. T umour-stroma interactions-reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland. Breast Cancer Res 2001 ; 3 : 365-72 (Pubitemid 34196362)
62. Schaefer L, Schaefer R M. Proteoglycans: From structural compounds to signalling molecules. Cell Tissue Res 2010 ; 339 : 237-46
63. Skandalis S S, Labropoulou V, Ravazoula P, et a l. V ersican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-Appearing microcalcifi cations in non-palpable breast carcinomas. BMC Cancer 2011 ; 11 : 314-26
64. Kass L, Erler J T, Dembo M, Weaver V M. M ammary epithelial cell: Infl uence of extracellular matrix composition and organization during development and tumorigenesis. Int J Biochem Cell Biol 2007 ; 39 : 1987-94 (Pubitemid 47369248)
65. Yoneda A, Lendorf M E, Couchman J R, Multhaupt H AB. B reast and ovarian cancers: A survey and possible roles for the cell surface heparin sulphate proteoglycans. J Histochem Cytochem 2011 ; 60 : 9-21
66. Esko JD, Kimata K, Lindahl U. Proteoglycans and sulfated glycosaminoglycans. In Varki A, Cummings RD, Esko JD, et al ., eds. Essentials of Glycobiology, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 2009 : Chapter 16
67. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: Novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J 2010 ; 277 : 3904-23
68. Bernert B, Porsch H, Heldin P. H yaluronan synthase 2 (HAS2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J Biol Chem 2011 ; 286 : 42349-59
69. Viola M, Vigetti D, Genasetti A, et al. Molecular control of the hyaluronan biosynthesis. Connect Tiss Res 2008 ; 49 : 111-14
70. Corte MD, Gonzalez LO, Lamelas ML, et al. Expression and clinical signifi cation of cytosolic hyaluronan levels in invasive breast cancer. Breast Cancer Res Treat 2006 ; 97 : 329-37 (Pubitemid 43945763)
71. Sunil N, Srinivasan N, Aruldhas MM, Govindarajulu P. Impact of oestradiol and progesterone on the glycosaminoglycans and their depolymerising enzymes of the rat mammary gland. Acta Physiol Scand 2000 ; 168 : 385-92 (Pubitemid 30135785)
72. Wight TN. Versican: A versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 2002 ; 14 : 617-23 (Pubitemid 35247746)
73. Iozzo RV, Schaefer L. Proteoglycans in health and disease: Novel regulatory signalling mechanisms evoked by the small leucinerich proteoglycans. FEBS J 2010 ; 277 : 3864-75
74. Goldoni S, Seidler D G, Heath J, et a l. A n antimetastatic role for decorin in breast cancer. Am J Pathol 2008 ; 173 : 844-55
75. Goldoni S, Iozzo RV. Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 2008 ; 123 : 2473-9
76. Troup S, Njue C, Kliewer E V, et a l. R educed expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003 ; 9 : 207-14 (Pubitemid 36109735)
77. L ö fgren L, Sahlin L, Jiang S, et al. Expression of syndecan-1 in paired samples of normal and malignant breast tissue from postmenopausal women. Anticancer Res 2007 ; 27 : 3045-50 (Pubitemid 47607525)
78. Kousidou OC, Berdiaki A, Kletsas D, et al. Estradiol-estrogen receptor: A key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2008 ; 2 : 223-32
79. Lundstr ö m E, Christow A, Kersemaekers W, et a l. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002 ; 186 : 717-22 (Pubitemid 34494352)
80. Wiebe JP. Progesterone metabolites in breast cancer. Endocr Related Cancer 2006 ; 13 : 717-38 (Pubitemid 44763254)
81. Wiebe JP, Beausoleil M, Zhang G, Cialacu V. Opposing actions of the progesterone metabolites, 5 〈-dihydroprogesterone (5 〈 P) and 3 〈-dihydroprogesterone (3 〈 HP) on mitosis apoptosis, and expression of Bcl-2, Bax and p21 in human breast cell lines. J Steroid Biochem Mol Biol 2010 ; 118 : 125-32
82. Wiebe J P, Lewis M J, Cialacu V, Pawlak K J, Zhang G. The role of progesterone metabolites in breast cancer: Potential for new diagnostics and therapeutics. J Steroid Biochem Mol Biol 2005 ; 93 : 201-8 (Pubitemid 40602493)
83. Murkes D, Conner P, Leifland K, et a l. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens- medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril 2011 ; 95 : 1188-91
84. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998 ; 69 : 963-9 (Pubitemid 28193936)
85. Wood C E, Register TC, Lees CJ, Chen H, Kimrey S, Cline JM. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 2007 ; 101 : 125-34 (Pubitemid 46115419)
86. H ü mpel M, Dü sterberg B, Beier S, Schuppler J, Gunzel P, Elger W. The role of pharmacokinetics in preclinical safety studies of synthetic sex steroids. In Gregoire AT, Blye RP, eds. Contraceptive Steroids-Pharmacology and Safety. New York: Plenum Press, 1986 :47-65
87. Gompel A. M icronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012 ; 15 : 18-25
88. Clavel-Chapelon F, the E3N Group. E3N, aFrench cohort study on cancer risk factors. Eur J Cancer Prev 1997 ; 6 : 473-8 (Pubitemid 28020418)
89. Bergströ m A, Pisani P, Tenet V, Wolk A, Adami H O. O verweight as an avoidable cause of cancer in Europe. Int J Cancer 2001 ; 91 : 421-30 (Pubitemid 32049639)
90. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005 ; 114 : 448-54 (Pubitemid 40279968)
91. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008 ; 107 : 103-11 (Pubitemid 350179584)
92. Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation infl uence risks? J Clin Oncol 2009 ; 31 : 5138-43
93. Levine H, Watson N. Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril 2000 ; 73 : 516-21 (Pubitemid 30109647)
94. Nahoul K, Dehennin L, Scholler R. Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J Steroid Biochem 1987 ; 26 : 241-9 (Pubitemid 17040129)
95. Nahoul K, Dehennin L, Jondet M, Roger M. Profi les of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993 ; 16 : 185-202
96. Allen N E, Tsilidis K K, Key T J, et a l. M enopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010 ; 172 : 1394-403
97. Ahn J, Schatzkin A, Lacey J V, et a l. A diposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007 ; 167 : 2091-102 (Pubitemid 350036709)
98. Goodwin PJ, Ennis M, Bahl M, et al. High insulin levels in newly diagnosed breast cancer patients refl ect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009 ; 114 : 517-25
99. Gunter M J, Hoover D R, Yu H, et a l. I nsulin, insulin-like growth factor-1, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009 ; 101 : 48-60
100. Gupta K, Krishnaswamy G, Karnad A, Peiris AN. Insulin: A novel factor in carcinogenesis. Am J Med Sci 2002 ; 323 : 140-5
101. Lawlor D A, Smith G D, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: Fi ndings from the British Women's Heart and Health Study. Cancer Causes Control 2004 ; 15 : 267-75 (Pubitemid 38988035)
102. Writing Group for the PEPI Trial: Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996 ; 275 : 370-5
103. Pelissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Jondet M. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 2001 ; 40 : 85-94 (Pubitemid 33042468)